SCHEMBL3863536

SCHEMBL3863536

CC(C#N)c1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDPK1 O15530 1/20 0.35
AKR1C3 P42330 2/20 0.34
AKR1C2 P52895 2/20 0.34
MME P08473 1/20 0.34
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
HSD11B1 P28845 1/20 0.32
APP P05067 2/20 0.32
PTGS1 P23219 3/20 0.31
MEN1 O00255 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6565085 0.84 CYP11B1 (0.40) CYP11B1CYP11B2ESR1ESR2
SCHEMBL10702777 0.82 ALDH1A1 (0.42) CYP11B1CYP11B2GAAESR1ESR2
SCHEMBL27944345 0.82 CYP11B1 (0.39) CYP11B1CYP11B2ESR1ESR2CYP1A2
SCHEMBL9176198 0.80 ESR1 (0.39) CYP11B1CYP11B2CES2CES1GAA
SCHEMBL9510754 0.80 RAB9A (0.41) CYP11B1CYP11B2TSHRLMNACYP1A2
SCHEMBL29724711 0.77 AKR1C3 (0.59) SMN1; SMN2AKR1C3AKR1C2APPPTGS1
SCHEMBL7037138 0.77 AKR1C3 (0.59) SMN1; SMN2AKR1C3AKR1C2APPPTGS1
SCHEMBL13776977 0.77 AKR1C3 (0.59) SMN1; SMN2AKR1C3AKR1C2APPPTGS1
SCHEMBL3718088 0.77 CES2 (0.39) CES2CES1SMN1; SMN2ESR1ESR2
SCHEMBL6565095 0.77 ESR1 (0.43) CYP11B1CYP11B2GAAAKR1C3ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598243-B2 inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases MERCK & CO., INC. (US) 2009-10-06 US disclosed
EP-1622916-A4 HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2008-11-05 EP disclosed
US-20080081803-A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2008-04-03 US disclosed
EP-1622916-A2 HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2006-02-08 EP disclosed
WO-2004094371-A2 HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081803-A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity CCR1, CCR5, CCR2 CYP11B1 712/4885CYP11B2 567/4885CES2 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.